Exagamglogene Autotemcel (CASGEVY) Recommended for Reimbursement in Canada for Sickle Cell and Thalassemia Diseases

The Sickle Cell Awareness Group of Ontario and the other member organizations of the Global Action Network for Sickle Cell & Other Inherited Blood Disorders (GANSID) submitted reimbursement feedback to the Canadian Agency for Drugs and Technologies in Health (CADTH) now known as Canada’s Drug Agency (CDA) to reimburse the treatment of patients 12 years of age and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs); and transfusion-dependent β-thalassemia (TDT) with CASGEVY.

This advocacy work has received a positive draft recommendation for reimbursement.

Submissions:

May 2024: SCAGO, GANSID and other patient groups' submissions:

Link: https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0830-exa-cel-SCD_Patient_Clinician_Group_Input_Revised.pdf

Reimbursement Recommendations:

The CDA is recommending reimbursement of this therapy for those who meet the stipulated conditions. Read the CDA’s recommendations with the conditions on reimbursing the curative treatment at the link: https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0831_Casgevy_Draft_Recommendation.pdf